Determination of rivaroxaban in human plasma samples

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 2, 2012, Pages 178-184

  Harenberg, Job ^a   Erdle, Sandra ^a   Marx, Svetlana ^a   Krämer, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

activated partial thromboplastin time; chromogenic substrate methods; prothrombin time assay; prothrombinase induced clotting time assay; rivaroxaban; thromboplastin reagent

Indexed keywords

BLOOD CLOTTING FACTOR 10A; RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; GERIATRIC PATIENT; GLOMERULUS FILTRATION; HUMAN; KIDNEY DISEASE; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM; TREATMENT DURATION;

BLOOD COAGULATION; FACTOR XA; HEMORRHAGE; HUMANS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THIOPHENES; VENOUS THROMBOSIS;

EID: 84858131682     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1301415     Document Type: Article

References (34)

1. Geerts WH, Bergqvist D, Pineo GF., et al. American College of Chest Physicians. Prevention of venous thromboembolism: evidence-based clinical practice guidelines. Chest: 2008; 133 6, Suppl 381S 453S
2. Singer DE, Albers GW, Dalen JE., et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: evidence-based clinical practice guidelines. Chest: 2008; 133 6, Suppl 546S 592S
3. Ansell J, Hirsh J, Hylek E., et al. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: evidence-based clinical practice guidelines. Chest: 2008; 133 6, Suppl 160S 198S
4. Hirsh J, Bauer KA, Donati MB., et al. American College of Chest Physicians. Parenteral anticoagulants: evidence-based clinical practice guidelines. Chest: 2008; 133 6, Suppl 141S 159S
5. Schulman S, Beyth RJ, Kearon J, Levine MN.; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: evidence-based clinical practice guidelines. Chest: 2008; 133 6, Suppl 257S 298S (Pubitemid 351892969)
6. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost: 2011; 37 3 252 266
7. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost: 2009; 35 5 515 524
8. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther: 2005; 78 4 412 421 (Pubitemid 41393676)
9. ROCKET AF Investigator II; Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
10. Lippi G, Franchini M, Targher G. Rivaroxaban for thromboprophylaxis. N Engl J Med: 2008; 359 20 2175 2176
11. Fox KA, Piccini JP, Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J: 2011; 32 19 2387 2394
12. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet: 2011; 50 10 675 686
13. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillationregulatory considerations. N Engl J Med: 2011; 365 17 1557 1559
14. Granger CB, Alexander JH, McMurray JJ., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
15. Kubitza D, Becka M, Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol: 2010; 70 5 703 712
16. Asmis LM, Alberio L, Angelillo-Scherrer A., et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res: 2011;; August 11 [Epub ahead of print]
17. Samama MM, Contant G, Spiro TE., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators. Thromb Haemost: 2012; 107 in press
18. Harenberg J. SSC project report: determination of anticoagulant effects of rivaraoxaban: towards a recommendation for assays. Available at: http://www.isth2011.com/ssc-program.html#ssc-session-14. Assessed Sept 20, 2011
19. Roehrig S, Straub A, Pohlmann J., et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem: 2005; 48 19 5900 5908 (Pubitemid 41324601)
20. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis: 2011; 32 3 267 271
21. Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis: 2011; 22 637 641
22. Samama MM, Martinoli JL, LeFlem L., et al. Assessment of laboratory assays to measure rivaroxabanan oral, direct factor Xa inhibitor. Thromb Haemost: 2010; 103 4 815 825
23. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost: 2011; 9 1 226 228
24. Calatzis A, Spannagl M, Gempeler-Messina P., et al. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants. Haemostasis: 2000; 30 suppl 2 172 174 (Pubitemid 32234159)
25. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost: 2007; 33 5 503 507 (Pubitemid 47105740)
26. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res: 2008; 123 2 396 403
27. Harenberg J, Giese C, Marx M, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost: 2012; 38 1 16 22
28. Perzborn E, Harwardt M, Samama MM. Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor. ISTH: 2009;, abstract PP-MO-185
29. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med: 2011; 49 5 755 757
30. Favaloro EJ, Lippi G. Coagulation update: what's new in hemostasis testing? Thromb Res: 2011; 127 Suppl 2 S13 S16
31. http://www.isth.org/default/index.cfm/ssc1/2011-ssc-subcommittee-minutes/ 2011-control-of-anticoagulation-minutes/
32. Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb: 2002; 32 4 174 179 (Pubitemid 37449310)
33. Gehrie E, Laposata M. Test of the month: The chromogenic antifactor Xa assay. Am J Hematol: 2011;; DOI: 10.1002/ajh. 22222
34. Harenberg J, Marx S, Erdle S, Krämer R. Determination of the anticoagulant effects of new oral anticoagulants-an unmet need. Expert Rev Haematol: 2012; 5 in press